Active	Status	Sponsor type	Region	Phase	Filter
14 Active 0 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Haverkos, Bradley
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies	Completed	1/2	64	US, RoW	VRx-3996, Nanatinostat, Valganciclovir	Viracta Therapeutics, Inc.	Epstein-Barr Virus Associated Lymphoma, Lymphoproliferative Disorders	04/23	05/23
Lanning, Ryan M
NCT05053737: Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC	Completed	1	11	US	Atezolizumab, MPDL3280A, RG7446, Tecentriq, Stereotactic Body Radiation Therapy, SBRT	University of Colorado, Denver, Genentech, Inc.	Squamous Cell Carcinoma of Head and Neck	11/23	06/24
Robin, Tyler
POTEN-C, NCT03525262: Prostate Oncologic Therapy While Ensuring Neurovascular Conservation	Active, not recruiting	2	124	US	30Gy (Gray) planning target volume (PTV)	University of Texas Southwestern Medical Center, Boston Scientific Corporation	Prostate Cancer Adenocarcinoma	05/27	05/27